The BRAF inhibitors vemurafenib and dabrafenib have shown significant improvement in patient survival compared with standard therapy in BRAF V600-mutant metastatic melanoma. Results suggest vemurafenib seems to be more nephrotoxic than dabrafenib and renal toxicity seems to be more prevalent among male patients with melanoma. Dermatologists, oncologists, and nephrologists need to be aware of this potential hazard.
- Review of FDA Adverse Event Reporting System (FAERS) data for both agents for renal toxic effects
- From July 2011 through June 2...